BioSpace News Archive

AZTherapies, Inc. , a biopharmaceutical company in advanced clinical trials to treat neuroinflammatory diseases, today announced the appointment of Marc de Garidel to the position of Chief Executive Officer. Mr. de Garidel has also joined the company’s Board of Directors. He succeeds company Founder and former CEO David R. Elmaleh, Ph.D., who is remaining as Executive Chairman of the AZTherapies Board of Directors and Chief Scientific Officer. “I ca

Safety and efficacy to be evaluated in patients with relapsed or refractory blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia and high-risk myelodysplastic syndrome

Including Positive Data from Ongoing Open Label Arm of Resmetirom 52 Week Phase 3 MAESTRO-NAFLD-1 Trial

CNS Pharmaceuticals, Inc., a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, announced that the Company’s GMP manufacturer partner NCK A/S, received a Certificate of Analysis for its Active Pharma Ingredient, clearing it for use in the production of Berubicin.

Molecular diagnostics company Genetic Technologies Ltd, provides the following update to the market on the development of the Company’s COVID-19 Risk Test.

Leading Research and Innovation Hub’s elPrep5 Big Data Platform Performs DNA Analysis up to 16 Times Faster Than Previous Options [01-October-2020] LEUVEN, Belgium , Oct. 1, 2020 /PRNewswire/ -- Today, imec , a world-leading research and innovation hub in nanoelectronics and digital technologies, announced elPrep5, the newest version of its software platform for DNA an

The CARE for COVID Program helps employers to make informed decisions about who to test, which test to use, and when to test to help employees return to work safely [01-October-2020] ALISO VIEJO, Calif. , Oct. 1, 2020 /PRNewswire/ -- Ambry Genetics (Ambry), a leading clinical genetic testing lab, is launching its CARE for COVID Program with Western Springs Schoo

Boehringer Ingelheim today announced that Lars Dreesmann , PhD, has been named President of the company’s US biopharmaceutical development and manufacturing business, Boehringer Ingelheim Fremont

TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced today it has secured a €7M state-guaranteed loan ( Prêt Garanti par l’Etat , or PGE). The loan was awarded by BNP Paribas, CM-CIC and bpifrance. Initiated by the French Government to support companies during the COVID-19 crisis, the PGE is a bank loan with a fixed interest rate ranging from 0.25% and 1.

Imago BioSciences, Inc . (“Imago”) a clinical-stage biopharmaceutical company developing innovative treatments for myeloid diseases, today announced that the first patient has been dosed in the first Imago-sponsored Phase 2b clinical trial of bomedemstat (IMG-7289) for the treatment of essential thrombocythemia (ET). “We are excited to start this study. There are many patients with essential thrombocythe